ProShare Advisors LLC Has $6.14 Million Stock Holdings in Humana Inc. $HUM

Posted by George Bondi on May 23rd, 2026

ProShare Advisors LLC raised its holdings in shares of Humana Inc. (NYSE:HUM – Free Report) by 13.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,956 shares of the insurance provider’s stock after purchasing an additional 2,762 shares during the quarter. ProShare Advisors LLC’s holdings in Humana were worth $6,136,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Sound View Wealth Advisors Group LLC lifted its holdings in Humana by 3.5% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,060 shares of the insurance provider’s stock valued at $272,000 after purchasing an additional 36 shares during the last quarter. Unison Advisors LLC lifted its holdings in shares of Humana by 0.4% during the third quarter. Unison Advisors LLC now owns 10,137 shares of the insurance provider’s stock worth $2,646,000 after buying an additional 37 shares in the last quarter. CoreCap Advisors LLC lifted its holdings in shares of Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Insigneo Advisory Services LLC lifted its holdings in shares of Humana by 3.0% during the third quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider’s stock worth $386,000 after buying an additional 43 shares in the last quarter. Finally, Columbus Macro LLC lifted its holdings in shares of Humana by 5.5% during the fourth quarter. Columbus Macro LLC now owns 821 shares of the insurance provider’s stock worth $210,000 after buying an additional 43 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Up 1.4%

Shares of NYSE HUM opened at $307.79 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $315.66. The stock has a market capitalization of $36.95 billion, a P/E ratio of 32.92, a PEG ratio of 2.82 and a beta of 0.68. The stock’s fifty day moving average is $218.13 and its 200 day moving average is $227.64.

Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The company had revenue of $39.65 billion for the quarter, compared to analysts’ expectations of $39.37 billion. During the same quarter last year, the business earned $11.58 earnings per share. Humana’s revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. Sell-side analysts forecast that Humana Inc. will post 9.01 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a $0.885 dividend. The ex-dividend date is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. Humana’s dividend payout ratio (DPR) is presently 37.86%.

Insider Activity at Humana

In related news, insider Sanjay K. Shetty purchased 810 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were bought at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the transaction, the insider owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Oppenheimer raised Humana from an “outperform” rating to an “outperform” rating in a report on Wednesday. Piper Sandler reissued a “neutral” rating and set a $254.00 target price (up from $182.00) on shares of Humana in a report on Wednesday, May 13th. Zacks Research raised Humana from a “strong sell” rating to a “hold” rating in a report on Wednesday, May 13th. Raymond James Financial reissued an “outperform” rating and set a $260.00 target price on shares of Humana in a report on Friday, May 1st. Finally, Morgan Stanley lifted their target price on Humana from $146.00 to $217.00 and gave the stock an “underweight” rating in a report on Friday, May 15th. Nine equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $263.35.

Get Our Latest Stock Analysis on HUM

About Humana

(Free Report)

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.